Diseases and conditions affecting the lower urinary tract are a leading cause of dysfunctional sexual health, incontinence, infection and kidney failure. The growth, differentiation, and repair of the bladder's epithelial lining is regulated by fibroblast growth factor (FGF)-7 and -10 via a paracrine cascade originating in the mesenchyme (lamina propria) and targeting the receptor for FGF-7 and -10 within the transitional epithelium (urothelium). Recombinant FGF-7 and -10 induce proliferation of human urothelial cells in vitro and transitional epithelium of wild-type and FGF7-null mice in vivo. To determine the extent that induction of urothelial cell proliferation during the bladder response to injury is dependent on FGF-7, an animal model of partial bladder outlet obstruction was developed. Unbiased stereology was used to measure the percentage of proliferating urothelial cells between obstructed groups of wild-type and FGF7-null mice. The stereological analysis indicated that a statistical significant difference did not exist between the two groups, suggesting that FGF-7 is not essential for urothelial cell proliferation in response partial outlet obstruction. In contrast, a significant increase in FGF-10 expression was observed in the obstructed FGF-7 null group, indicating that the compensatory pathway that functions in this model result in urothelial repair.
INTRODUCTION
Bladder outlet obstruction is a medical condition that can affect men, women and children.
Lower urinary tract obstruction can lead to voiding dysfunction as well as kidney failure. Many men suffer from obstruction due to benign prostatic hypertrophy, leading to both medical and psychosocial dysfunction (2) . Associated with these dysfunctions are severe losses of smooth muscle function and bladder contractility, or progression of the bladder towards conditions of severe hypertrophy and hypercontraction (3) . Incomplete bladder emptying in patients is also a risk for urinary tract infection. In addition, children born with congenital forms of bladder outlet obstruction such as posterior urethral valves or children born with functional bladder obstruction, such as in spina bifida patients, can lead to significant urinary incontinence and renal dysfunction.
Transitional epithelium that lines the urinary tract exhibits one of the slowest turnover rates among mammalian epithelia, estimated at once every 365 days (4) (5) (6) (7) . Although the urothelial cells that comprise this epithelia rest in G 0 during normal conditions, they remain active in metabolic processes that accompany shape change during bladder emptying and filling. In response to injury, transitional epithelium exhibits a remarkable ability to turnover within 24-48 hours after the initial insult. The identity of the mitogenic signal that gives rise to basal urothelial cell proliferation has been attributable to growth factors. Such factors are classified as either paracrine, autocrine, or juxtacrine, depending on the originating and target cell type. Mitogens known to act on human urothelial cells include epidermal growth factor (8) , heparin-binding epidermal growth factor-like growth factor (9) , activators of the estrogen receptor (10, 11) , transforming growth factor-α (12), fibroblast growth factor-1 (12) , and fibroblast growth factor-10 (13).
The model most frequently used to study the urothelial response to injury is partial outlet obstruction of the bladder via urethral ligation (14) . The wound healing response appears to be constant from animal model to animal model and mimics the clinical response seen in humans (15- 17). Such events include urothelial cell proliferation within 24-48 hr, subsequent hypertrophy of the bladder wall, and alterations in detrusor muscle and the extracellular matrix. Experimental animal models have been exploited to study bladder dysfunctions that are similar to those observed in men with benign prostatic hyperplasia (18, 19) . Furthermore, this experimental model has direct implications for other clinical disease states such as congenital (i.e. posterior urethral valves) or acquired (urethral stricture or bladder neck contraction) urinary tract obstruction.
Fibroblast growth factor-7 (FGF-7) is a 194 aa polypeptide implicated in both the induction of basal urothelial cell proliferation and the expansion of transitional epithelium (14, 20) . Also known FGF-7 and FGF-10 are considered to be paracrine factors, originating in mesenchyme but active only upon epithelium (13, 21, 22, 25) . The formation of a specific FGF7-containing FGFR signal transduction complex requires 3 components: the FGF-7 polypeptide, proteoglycans that contain either heparan-(26, 27), dermatin-(28), or chondroitin-(29) sulfate, and an alternatively-spliced tyrosine kinase protein product of the FGFR2 gene (7, 30) , and (27). This receptor, known as the keratinocyte growth factor receptor (KGFR), the FGFR2IIIb splice variant, or the FGFR2 isoform 2 splice variant, is a cell-surface transmembrane protein that undergoes dimerization upon ligand binding and subsequent autophosphorylation of intracellular tyrosine residues (31). Allelic mutations in the FGFR2 exons that encode the isoform 2 splice variant are known to give rise to a number birth defects that include craniosynostosis syndromes (32). It is believed that the FGFR2 isoform 2 splice variant serves as a receptor for both FGF-7 and FGF-10.
Mice that contain a targeted disruption of the FGF-7 gene exhibit defects in (i) cells that give rise to the hair shaft (33), (ii) ureteric bud outgrowth (34), and (iii) stratification of bladder urothelium (35). The collective evidence demonstrates an essential role for FGF-7 in development, growth, differentiation, and homeostasis of the mucosal lining of the urinary tract. In contrast to the FGF-7 null mouse, the FGF-10 null mouse lacks limb bud initiation and lung development (36). In addition, the FGF-10 null mouse exhibits gross anatomical defects in the urinary tract with includinga urothelium that fails to stratify (37). Consequently, FGF-10 null mice die at birth, precluding their use in experimental models of partial bladder obstruction.
This study demonstrated the mitogenic potential of FGF-7 on human and murine urothelial cells. The growth factor was found to stimulate resting cells to exit from G 0 and traverse the cell cycle. To determine if the mitogen was responsible for the induction of urothelial cell proliferation during the initial response of the bladder to injury, we examined whether there was a difference in the urothelial response to injury between wild-type and FGF7-null mice in a model of partial outlet obstruction. Stereological analysis of obstructed bladders revealed that a statistically significant difference did not exist indicating that FGF-7 is not essential for urothelial cell proliferation during the response to partial outlet obstruction of the urinary bladder. Further stereological analysis revealed a significant fold increase of FGF-10 synthesis in obstructed FGF7-null mice via a compensatory paracrine mechanism. . These data are consistent with the deduced primary structure being the mature, secreted form of bladder FGF-7.
Distribution and Characterization of FGF-7 Sequences in the Human Genome
The distribution of the bladder FGF-7 cDNA sequence in the human genome is shown in Table   1 . Regions of identity or near-identity were localized to chromosomes 9, 15, 18, and 21. Because our bladder FGF-7 cDNA sequence does not contain 5'-and 3'-mRNA sequences, we performed an analogous search with the reference sequence assigned to the FGF-7 mRNA by the National Center for Biotechnology Information. In Table 1 , the bracketed row of data represents additional genomic regions detected with the full-length 3,853 base mRNA reference sequence. Five, four, two and two regions of identity or near-identity were localized to chromosomes 9, 15, 18, and 21, respectively.
Of the 4 chromosomes identified to contain FGF-7 sequences, we were able to localize the gene that encodes FGF-7 to chromosome 15. The extent to which introns 2 and 3, and exons 3 and 4, of the chromosome 15 FGF-7 were distributed among chromosomes 9, 18, and 21 was also investigated ( Table 3 ). The size of exons 3 and 4 were each almost perfectly conserved among chromosomes 18, 21, one region located in the middle of the p arm (Chr 9pm), and two regions proximal to the centromere (Chr 9qc) and telomere (Chr 9qt) of the q arm of chromosome 9. The length of the chromosome 18 FGF-7 sequence is nearly identical to the length of the chromosome 15 FGF-7 gene sequence. Scattered over these 3 chromosomes are 7 regions that exhibit near-identical sequences. We considered these regions to be duplications of the FGF-7 gene sequences present on chromosome 15. These duplicated copies contain only portions of the FGF-7 gene sequence ( Figure 1 ). Such duplications for the FGF-7 gene have been previously detected by Southern blotting (38) and by fluorescence in situ hybridization (39). In this latter study, the duplications were visualized on chromosomes 2, 9 (two spots), 15, 18 (two spots), and 21 (two spots). Our sequence analysis differs from these results in that no sequences were identified to account for the chromosome 2 spot.
Five copies of the duplicated sequences were localized to chromosome 9 (Table 3 and Figure 1 ).
Among the conserved copies, two gap-containing sequences were identified proximal to the centromere on the 9p arm (9pc) and proximal to the telomere on the 9q arm (9pt). Motifs and sites for post-translational modification that are predicted to occur in the wild-type FGF-7 sequence are also shown in Figure 2 . Naturally occurring FGF-7 proteins are predicted to contain sites for N-linked glycosylation (Asn16), casein kinase II phosphorylation site (Ser18 and Thr150), phosphorylation site by protein kinase C (Ser124) and amidation (Gly147). A 24 aa region (Gly96-Tyr119) is the consensus sequence for the FGF family of heparin-binding polypeptides (40) and a potential transmembrane segment (41). The "glycine box" sequence (NQKGIPVRG, residues 139 -147) (42) is the major determinant for the specificity of the binding of FGF-7 to heparan sulfate-FGFR complexes (40). Residues that have been implicated in binding to heparin (23) (1) were identified as Arg43, Asn117, Asn139, Gln140, Val145,Lys148, Asn154, Lys155, and Thr156
( Figure 2 ). These residues form a positively charged motif that is present on the surface of the macromolecule (Supplemental Figure 2) . The heparin-binding motif of rFGF7-His is therefore exposed to the solvent, and, more importantly, available to bind to and interact with heparan-, chondroitin-, or dermatin-sulfate proteoglycans.
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Expression, Isolation, and Characterization of Recombinant FGF-7 in Escherichia coli
The expression of recombinant FGF-7 was realized as a fusion protein with a hexamer of His residues at the C-terminus ( Figure 2 and Supplemental Figure 2 ). This recombinant fusion protein, designated rFGF7-His, was found to comprise 1-2% of the total cellular protein and to partition equally between the soluble and insoluble fractions of lysed BL21trxB(DE3) E. coli (data not shown). We pursued the characterization of the soluble form of rFGF7-His with respect to 1) intactness, 2) ability to interact with heparin, 3) folding, and 4) biological activity in vitro. 
FGF-7 is a Non-Essential Mitogen During Partial Bladder Outlet Obstruction
An experimental mouse model of partial bladder outlet obstruction was developed wherein a partial surgical ligature was placed around the urinary bladder outlet. In this model, animals that underwent partial ligation exhibited bladders that were abnormally distended. The hallmark feature of transitional epithelium over the 8 days of obstruction was the marked increase of stratification of control animals (data not shown), a result that indicated that partial outlet obstruction of the bladder was successfully accomplished by ligation of the urethra.
In contrast to control and sham-operated animals, transitional epithelia from animals that underwent partial urethral ligation at the bladder neck exhibited marked immunoreactivity with antibodies specific for the Ki-67 nuclear antigen. The total number of Ki-67 positive cells, as well as the total number of urothelial cells, was determined by stereology ( Figure 6 ). Calculation of mean values is presented in Table 4 . The percentage of Ki-67 positive cells for obstructed wild-type and FGF7-null mice was calculated to be 1.78 ± 0.46 cells and 1.60 ± 0.94, respectively. A statistical comparison between these two groups with the student's t-test indicated that this difference was not significant.
FGF-10 is a Compensatory Mitogen During Partial Bladder Outlet Obstruction
Bladder specimens from mice subjected to partial outlet obstruction as described above were tested for FGF-10 expression. FGF7-null and WT mice were compared for differential FGF-10 expression among fibroblasts within the lamina propria using the same stereologic analysis as described above. The mean number of FGF-10 positively stained fibroblasts for the WT and the FGF7-null mice per bladder were 195 and 1086, respectively (Table 4) . This difference was statistically significant (p = 0.004) proving that FGF-10 expression was up-regulated in response to obstruction. The collective data support the hypothesis that FGF-10 is an essential and compensatory mitogen for murine urothelium turnover.
DISCUSSION
In animal models, partial outlet obstruction of the urinary bladder induced by urethral ligation elicits a 3-phase programmed response: (i) an initial hypertrophy phase, (ii) a compensatory phase, and (iii) a decompensatory phase (18, 47) . The early molecular response of the lamina propria and urothelium in response to outlet obstruction has been studied in the context of mesenchymalepithelial interactions, specifically the role of mesenchymal growth factors in the induction of urothelial cell proliferation (13, 15, (48) (49) (50) . In these models, FGF-7 mRNA has consistently been observed to be markedly upregulated in response to obstruction (14, 15, 47) . Our analysis of the FGF-7 gene indicated that while exons 3 and 4 were duplicated within the human genome, we found no evidence that full-length FGF-7 mRNAs could arise from any other locus than 15q15-q21.1.
Mesenchymal mediators of epithelial cell behavior, proliferation, and differentiation represent an important means of regulating development, homoeostasis, and the response to injury. In the urinary bladder, the paracrine mediator that has been most studied is FGF-7, a polypeptide synthesized and secreted by fibroblasts of the lamina propria (15, 20, (47) (48) (49) (50) . Our study demonstrates that this growth factor is a mitogen for human and murine urothelial cells of transitional epithelium, a result in agreement with prior reports that studied the effect of the purified factor on transitional epithelia from monkey (51), rat (51, 52), and murine (20, 35) sources.
Equivalent biological activities were observed for rFGF7-His (our preparations) and rFGF-7
(provided by Amgen as the pharmaceutical Palifermin) in assays that monitored the incorporation of The collective data prove our hypothesis that redundant mechanisms compensate for the lack of FGF-7 in FGF7-null mice that continue to exhibit proliferating urothelial cells in response to obstruction. The principal mitogenic candidate to compensate for the absence of FGF-7 was shown to be FGF-10, a known mitogen for urothelial cells in vitro and in vivo (13, 25) . Since both FGF-7
and FGF-10 can bind to, interact with, and stimulate a mitogenic signaling pathway through the same FGFR2 isoform 2 receptor (58), we conclude that FGFR2 isoform 2 remains functional in FGF7-null mice.
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Our prior report that the FGFR2 isoform 2 receptor is expressed by the superficial layer of transitional epithelia (25) is clinically significant because intravesical instillation of recombinant FGF-7 and -10 into the bladder lumen is predicted to trigger urothelial repair in response to injury due to obstruction. In addition, clinical conditions involving the urinary tract which cause epithelial damage such as infections and trauma leading to stricture disease, erosive disorders such as interstitial cystitis, and urinary tract disruption from transurethral resection surgery could be treated with mitogenic stimulation. Ongoing work is expected to lead to a better understanding of the steady-state interrelationships that involve urothelial cells, growth factors, matricellular proteins, the extracellular matrix, and the urothelial basement membrane. Advancing the study of FGF-7 and -10 is relevant because of the polypeptides' potential use as a clinical tool to treat, and ultimately cure, a variety of lower urinary tract conditions and diseases.
MATERIALS AND METHODS

Materials
Human urinary bladder cDNA was obtained from Invitrogen (Carlsbad, CA 
Isolation of rFGF7-His
Two types of recombinant (r) FGF-7 were used in this study. rFGF7-His, prepared in our laboratory as described in the Supplemental Materials Section and Palifermin (rFGF-7 lacking a C-terminal His-tag), prepared and provided to us by Amgen (59).
N-terminal Amino Acid Sequencing of rFGF7-His
A 1 ml fraction eluted from a nickel-chelate affinity chromatography column that contained 25 
H]-Thymidine Incorporation Assays of Urothelial Cell Proliferation
Because of the use of human transitional epithelial tissue for this study, these experiments were reviewed by the Institutional Review Board of Children's Hospital and Regional Medical Center.
Primary cultures of bladder urothelial cells derived from surgical explants were grown as previously described (13) . Assays of DNA synthesis of bladder urothelial cells were performed as previously described (13 Our preparations of rFGF7-His from soluble extracts were biologically active and the engineering of a C-terminal hexamer of histidine residues did not affect solubility, folding, or ability to bind to heparin. However, we found that the yields of bacterial rFGF7-His were disappointing, a result in agreement with a prior report that established that the growth factor exhibited limited stability in aqueous media, as it undergoes denaturation followed by aggregation at 37 °C (60). Therefore, we used Amgen's preparations of active recombinant FGF-7 for use in assays where milligram quantities of the growth factor were needed, e.g. injection into mice.
Induction of Murine Urothelial Cell Proliferation
rFGF-7, lacking a C-terminal histidine tag and ending at Thr 165 (Figure 4 ), was obtained from
Amgen as the pharmaceutical Palifermin, and dissolved in vehicle (120 mM NaCl, 2.7 mM KCl, 4 mM NaH 2 PO 4 (pH 7.4), 5 µg ml -1 heparin) at a final growth factor concentration of 100 µg ml -1 .
One ml was administered daily by intraperitoneal injection into the neck folds of wild-type C57BL/6J mice. On day 15, mice were euthanized and their bladders were harvested en bloc by anatomical positioning on a paraffin block. Specimens were fixed with methyl Carnoy's solution for inserted into the bladder via the urethra and then removed, and the cavity was closed; and (3) a group (n=8) that underwent ligation at the bladder neck area. The partial ligation was performed with mice under anesthesia. Once adequate anesthesia was obtained, the abdominal cavity was opened, exposing the bladder and urethra. A 26-gauge angiocatheter was inserted into the bladder via the urethra and a 7-0-monofilament polyglyconate suture was tied around the urethra at the bladder neck. The angiocatheter was then removed and reinserted to ensure partial outlet obstruction was obtained. Partial outlet obstruction was confirmed by observing urine flow with gentle extrinsic bladder compression. The abdomen was then closed, mice were allowed to recover, and housed for 8 additional days. Mice were sacrificed; the bladder was excised, pinned to a paraffin block, fixed in Methyl Carnoy's solution, and sectioned according the principles of stereology (below). Diaminobenzidine colorimetric staining with primary monoclonal mouse anti-human FGF-10 IgG at a concentration of 15 µg ml -1 and goat anti-mouse horseradish-peroxidase conjugated IgG at 1:500 dilution was performed with 5% goat serum block. Slides were counter-stained with a 1:10 dilution of Gill's formula for 1 minute and fixed.
Stereology Procedures
Estimates of the number of total and proliferating (Ki represented by the section, the optical disectors sampled 1/100,000 th of the entire structure. Cell counts were summed from all disectors across all sections collected, and the total number was determined by multiplying the number counted by the inverse of the fraction sampled. Systematic random sampling has been determined to be fair because every part of the original structure had an equal probability of being selected due to the random position set within the first interval, and systematic random sampling offers additional advantages of efficiency (63). and Leu, Glu, and six His residues (residues 166-173). Diamond indicates site of putative amidation (Gly147). Asterisk indicates site of N-linked glycosylation (Asn16).
Filled circles indicate sites of casein kinase II phosphorylation (Ser18 and Thr150).
Arrow indicates sites of phosphorylation by protein kinase C (Ser124). Underlined residues represent the FGF family signature (Gly96-Tyr119) (Prosite Database). Bolded residues represent the glycine box (Asn139-Gly147). Black boxes with white letters designate residues implicated in the heparin-binding motif (Arg43, Asn117, Asn139, Gln140, Val145, Lys148, Asn154, Lys155, and Thr156). Table 4 for corresponding values. 
Methods: Isolation and Dideoxy Sequencing of FGF-7 from Human Urinary Bladder
A population of human bladder cDNAs was used as a template for Taq polymerization. One pair of oligonucleotide primers was synthesized: "NcoI", 5'-CATCCGGATCCATGGCTTGCAATGACATGACTCCA-3' and "XhoI", 5'-ACTCTCCGGCTACTCGAGAGTTATTGCCATAGGAAG-3'. These primers were designed to partially anneal to FGF-7 cDNA -the noncomplimentary regions encoded sites for the restriction endonucleases NcoI and XhoI. Initial PCR conditions employed were 1 cycle at 95 °C were archived as glycerol stocks and characterized with respect to insert size and dideoxy DNA sequencing. Clones that were identified as containing correctly oriented and in-frame inserts were designated pSTBlue-FGF7.
Methods: Cloning into the Bacterial Expression Vector pET21d
Six and one-half µg of pSTBlue-FGF7 were restricted with NcoI and XhoI endonucleases and electrophoresed through an agarose gel. The DNA of a 0.52 kbp band was excised from the gel, extracted, and ligated to the expression plasmid pET21d, previously prepared by incubation with
NcoI and XhoI and dephosphorylation with shrimp alkaline phosphatase. After transformation into BL21trxB(DE3) E. coli, recombinant colonies were generated by growth on Luria broth-agar plates that contained 50 µg ml -1 carbenicillin, stored as glycerol stocks, and designated pET21d-
FGF7
. The resultant open reading frame that included six C-terminal His residues generated a fusion protein designated as rFGF7-His. Methods: Expression, Isolation, and Characterization of Recombinant FGF-7 in E. coli
The insert coding region from pSTBlue1-FGF7 was recloned into the pET21d expression vector to ultimately form the expression plasmid pET21d-FGF7. The expression of recombinant FGF-7 (rFGF-7) by transformed E. coli was found to be dependent on the addition of isopropyl-1-thio-β-D-galactopyranoside, a reagent known to inactivate the lac repressor, thereby permitting synthesis of FGF-7 mRNA.
Methods: Stereology Procedures
Estimates in manuscript). The overlay of this stepping grid was placed randomly (independently) over the transitional epithelium, thus ensuring that each step was systematic and random. In our experiments, the optical disectors sampled 1/2500 th of the transitional epithelium. Combined with the 1/40 th of the structure represented by the section, the optical disectors sampled 1/100,000 th of the entire structure. Cell counts were summed from all disectors across all sections collected, and the total number was determined by multiplying the number counted by the inverse of the fraction sampled. Systematic random sampling has been determined to be fair because every part of the original structure had an equal probability of being selected due to the random position set within the first interval, and systematic random sampling offers additional advantages of efficiency (63).
Supplemental Figure 1 . Agarose gel electrophoresis of human urinary bladder FGF-7 cDNA.
Lane 1, 100-bp markers are indicated to the left of the figure in kbp Lane 2, RT-PCR DNA products encoding FGF-7 from oligonucleotide primers designed to generate rFGF7-His. Lane 3, RT-PCR DNA products encoding FGF-7 from oligonucleotide primers designed to generate wild-type rFGF-7. Shown is a fluorescent image generated by photography of the gel stained with Sybr Green I. The band at ~525 bp corresponds to FGF-7 cDNA.
Results: Isolation and Sequence Analysis of FGF-7 cDNA from Human Urinary Bladder
A partial cDNA fragment that encoded the mature, secreted form of FGF-7 was isolated from a human urinary bladder cDNA library by reverse transcription (RT) and PCR. Supplemental 
Results: Expression of Recombinant FGF7-His in E. coli
Two types of recombinant (r) FGF-7 were used in this study. rFGF-7 (lacking a C-terminal His-tag) was prepared and provided by Amgen as the pharmaceutical Palifermin (67). rFGF7-His was prepared as described below.
A loop of recombinant bacteria from a frozen glycerol stock was streaked on a plate of agar that contained Media A (Luria broth, 100 µg ml -1 carbenicillin, and 0.2% glucose) and incubated at 37 °C for 16-24 hr. A 50 ml starter culture in Media A was inoculated with a single colony and propagated until the optical density at 600 nm reached ∼0.6. After storage of the culture overnight at 4 °C, cells were recovered by sedimentation at 5000 x g, resuspended in 4 ml of Media A, and inoculated into 2 L of prewarmed Media A. Once the cultures reached an optical density at 600 nm of ∼0.6, isopropyl-1-thio-β-D-galactopyranoside was added to a final concentration of 1 mM. After 3-4 hrs of continued growth at 37 °C, cells were collected by sedimentation at 5,000 x g at 4 °C and frozen at -20 °C.
Luria broth used in these experiments contained peptone derived from meat so as to eliminate lactose that would normally be found in peptone derived from milk. We have found that lactose in the medium elicits premature activation of the T7lac promoter and of rFGF7-His synthesis. 
Isolation of rFGF7-His
Results: Distribution and Characterization of FGF-7 Sequences in the Human Genome
Supplemental Figure 3 
